Franklin Biotechnology Discovery Adv (FTDZX)
* As of 31-Mar-14
Quotes delayed, except where indicated otherwise. Currency in USD.
- No Headlines available for FTDZX at this time.
|Morningstar Overall Rating:|
|Annual Report Expense Ratio (net):||0.91%|
Performance & Risk
|5y Avg Return:||27.60%|
|Rank in Category (ytd):||48|
|% Rank in Category (ytd):||36.64%|
|Morningstar Risk Rating:||5|
The investment seeks capital appreciation.
Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified. View More